China Begins to export COVID-19 Vaccines
China Begins to export COVID-19 Vaccines while the effectiveness of Pfizer’s COVID-19 pneumonia vaccine is better than expected, China’s vaccine research and development has also progressed. The United Arab Emirates has begun to purchase the COVID-19 vaccine developed by China National Pharmaceutical Group, becoming the first outside China to approve the use of China’s COVID-19 vaccine candidate s country.
The Chinese state-owned Sinopharm Group is actively engaged in the research and development of the COVID-19 vaccine. At present, hundreds of thousands of people have been vaccinated urgently with two “COVID-19 inactivated vaccines” under the condition of “emergency use”. There has not been any serious adverse reaction. There are also people who left the country after vaccination, about 56,000, and no case of infection has been reported so far.
On Nov 09, 2020, Chinese Foreign Minister Wang Yi said in a ministerial video conference of the Cooperation Committee with Arab States that vaccine cooperation has become a bright spot in the joint fight against the epidemic between China and the region. The third phase of clinical trials of the world’s first COVID-19 pneumonia vaccine launched by China, the United Arab Emirates, and Bahrain is stable, and the number of people vaccinated has reached 44,000.
In addition, Liu Jingzhen, Chairman of Sinopharm, pointed out that its COVID-19 vaccine has been tested in more than ten countries and regions including the United Arab Emirates, Bahrain, Egypt, Jordan, Peru, Argentina, and Morocco.
Regarding the future production capacity of vaccines, Liu Jingzhen said that by the end of this year, Sinopharm’s COVID-19 vaccine production capacity can reach approximately 100 million doses. According to the requirements of the Chinese government, the production capacity will exceed 1 billion doses next year to ensure that the Chinese people in particular can be vaccinated.